33414482Kantarjian HM, Hughes TP, Larson RA, Kim DW, Issaragrisil S, le Coutre P, Etienne G, Boquimpani C, Pasquini R, Clark RE, Dubruille V, Flinn IW, Kyrcz-Krzemien S, Medras E, Zanichelli M, Bendit I, Cacciatore S, Titorenko K, Aimone P, Saglio G, Hochhaus ALeukemiaAntineoplastic Combined Chemotherapy Protocols; Leukemia, Myelogenous, Chronic, BCR-ABL PositiveFemale; Follow-Up Studies; Humans; Imatinib Mesylate; Male; Middle Aged; Prognosis; Pyrimidines; Survival RateLong-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis. Leukemia. 2021 02; 35(2):440-453.Leukemia2021-01-07T00:00:002021Long-term outcomes with frontline nilotinib versus imatinib in newly diagnosed chronic myeloid leukemia in chronic phase: ENESTnd 10-year analysis.prns:fullNamefull nameprns:hasAuthorListauthor listprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:hasSubjectAreaMajorTopicListhas major subject area listprns:hasSubjectAreaMinorTopicListhas minor subject area listprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:sortOrdersort orderprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed Identifiervivo:authorRankauthor rank in publicationAuthorshipDepartmentvivo:hasSubjectAreahas subject areavivo:hrJobTitleHR job titleInformation Resourcevivo:informationResourceInAuthorshipauthorsvivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcePositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD000971Procedures30624340.476235Antineoplastic Combined Chemotherapy ProtocolsD008875Concepts & IdeasLiving Beings1473249570.258811Middle AgedD005260Physiology1992444050.191167FemaleD006801Living Beings2262862810.130052HumansD008297Physiology1931408600.201617MaleAuthorship 14316630.1999940.1999941authors10.2511has subject areaMedicine-Hematology and OncologyD011379Procedures74536690.561447PrognosisD011743Chemicals & Drugs1373700.795259PyrimidinesD015996Concepts & Ideas45518560.724887Survival RateD000068877451260.961421Imatinib MesylateD005500Procedures76836160.590107Follow-Up StudiesD015464Disorders401730.886112Leukemia, Myelogenous, Chronic, BCR-ABL PositiveUniversity of ChicagoRichard A.LarsonRichard A. Larson41.78927490000000-87.601250000000001169Larson, Richard A.Professortrue1ProfessorProfessor